Zynex Medical Announces FDA Approval for Its IF8000 Interferential Device

LITTLETON, CO -- (MARKET WIRE) -- 02/26/2004 -- Zynex Medical (OTC BB: ZYNX) announces FDA approval for its Interferential Current (IFC) device for deep relief of pain and muscle related problems. The IF8000 is one of the most advanced IFC devices on the market today. The IF8000 has applications such as symptomatic pain relief of chronic intractable muscle pain, post-traumatic and post-surgical pain through the relaxation of muscle spasms, prevention of atrophy and an increase in local blood circulation and mobility. Employing a higher concentration of electrical current than a TENS device, IFC has been found to alleviate pain in patients who have not found relief through less intense therapeutic applications. IFC penetrates the skin deeper than a regular TENS unit preventing pain transmission and possibly even the release of the body's natural pain killers, endorphins. Highlighted Links http://www.zynexmed.com Thomas Sandgaard, CEO of Zynex Medical Holdings, Inc. commented, "We are very proud of our IF8000 device and have generated significant revenues in past years with this device and plan to continue steady growth in the coming years." About Zynex Medical, Inc.: Since 1996, Zynex has been a leading provider of relief for patients with functional disability through the creation, distribution and marketing of the highest quality electrotherapy products available today. Zynex continually strives to uphold its mission to improve the quality of life of patients suffering from debilitating pain or illness by providing the highest technology and service standards in the electrotherapy industry. Zynex offers patients a new lease on life through increased mobility and independence. "Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.